



Novartis Ireland Ltd
Vista Building,
Elm Park Business Campus
Merrion Road
Dublin 4
D04 A9N6
Ireland

Telephone +353-1-2601255

20th February 2024

NOTIFICATION OF SUPPLY SHORTAGE

Estradot® (estradiol) 37.5 microgram/24 hours, transdermal patch (PA0896/010/001) and **Estradot® (estradiol) 50 microgram/24 hours**, transdermal patch (PA0896/010/002).

Dear Healthcare Professional,

Novartis regret to inform you of a temporary interruption to the supply of Estradot® 37.5, and 50 microgram/24 hours, transdermal patches, due to increased demand which is exceeding our supply capabilities.

Stock of the affected **Estradot® 37.5 microgram (PA0896/010/001) and 50 microgram (PA0896/010/002) patches** will be **intermittently** affected throughout the periods outlined below. This is impacting all markets. We have increased manufacturing quantities significantly over the past several months and continue to improve supply in order to meet increasing demand.


Pack Strength	Date of Expected Shortage	Date of Expected availability of stock
Estradot® 37.5 microgram	31 st January 2024	End of June 2024
Estradot® 50 microgram	10 th January 2024	23 rd February 2024

Expected return dates are subject to change and any updates to these timelines will be communicated promptly with the IPU and the HPRA.

Please refer to the full summary of product characteristics (SmPC) on www.medicines.ie for further information on Estradot®.

Please do not hesitate to contact Novartis if you have any queries or concerns at the following email medinfo.dublin@novartis.com.

Yours sincerely,

DocuSigned by:


0125C2AA5DF64A1...
Agron Hasani M.D.
Country Head of Medical Affairs/Chief Medical Officer
Novartis Ireland Limited